CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...

The cognitive effects men with advanced prostate cancer experience during treatment may vary based on the therapy they ...

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

BALTIMORE, May 12, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Advanced ...

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...

Cancer patients in Central Pennsylvania now have greater access to an advanced prostate cancer treatment with the launch of ...